HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

Pham Long V.; Ramirez Santseharay; Gottwein Judith M.; Fahnoe Ulrik; Li Yi-Ping; Pedersen Jannie; Bukh Jens

首页> 外文期刊>Gastroenterology >HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

【24h】

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

机译：HCV基因型6A逃离鲁棒传染细胞培养模型的Velpatasvir，Pibrentasvir和Sofosbuvir的抗抵抗力

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND & AIMS: Chronic liver diseases caused by hepatitis C virus (HCV) genotype 6 are prevalent in Asia, and millions of people require treatment with direct-acting antiviral regimens, such as NS5A inhibitor velpatasvir combined with the NS5B polymerase inhibitor sofosbuvir. We developed infectious cell culture models of HCV genotype 6a infection to study the effects of these inhibitors and the development of resistance.

机译：背景和目标：亚洲丙型肝炎病毒（HCV）基因型6引起的慢性肝病在亚洲普遍存在，并且数百万人需要用直接作用的抗病毒方案治疗，例如NS5A抑制剂Velpatasvir与NS5B聚合酶抑制剂Sofosbuvir联合。我们开发了HCV基因型6A感染的传染性细胞培养模型，研究了这些抑制剂的影响和抗性的发展。

著录项

来源
《Gastroenterology》 |2018年第8期|共27页
作者
Pham Long V.; Ramirez Santseharay; Gottwein Judith M.; Fahnoe Ulrik; Li Yi-Ping; Pedersen Jannie; Bukh Jens;
展开▼
作者单位

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

Hvidovre Univ Hosp Dept Infect Dis Copenhagen Hepatitis Program CO HEP C Copenhagen Denmark;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
DAA; Escape Variants; Nucleotide Analog; In Vitro System;

机译：DAA;逃生变体;核苷酸类似物;体外系统;

相似文献

外文文献
中文文献
专利

1. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models [J] . Pham Long V., Ramirez Santseharay, Gottwein Judith M., Gastroenterology . 2018,第8期

机译：HCV基因型6A逃离鲁棒传染细胞培养模型的Velpatasvir，Pibrentasvir和Sofosbuvir的抗抵抗力
2. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study [J] . Jacobson Ira M., Asselah Tarik, Nahass Ronald, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第6期

机译：在DAA初次感染1-6型HCV的患者中，Sofosbuvir / Velpatasvir / Voxilaprevir进行了8周的随机3期试验，与Sofosbuvir / Velpatasvir进行了12周的随机试验比较：POLARIS-2研究
3. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study [J] . Foster Graham R., Thompson Alex J., Ruane Peter J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir / Velpatasvir / Voxilaprevir的随机相3试验8周和Sofosbuvir / Velpatasvir为基因型3 HCV感染和肝硬化的患者进行12周：Polaris-3研究
4. Detection of infectious Cryptosporidium in treated drinking water usingmultiple cell culture assays and genotyping [C] . Anne Johnson, George Di Giovanni, Paul Rochelle AWWA water quality technology conference exposition . 2007

机译：使用多种细胞培养测定法和基因分型法检测经过处理的饮用水中的隐孢子虫感染性
5. Infectious disease dynamics and the direct and indirect effects of an escaped viral-resistance transgene on plant fitness in a wild squash. [D] . Sasuclark, Miruna Ariadna. 2010

机译：传染病动态以及逃逸的抗病毒转基因对西葫芦植物适应性的直接和间接影响。
6. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a 2b and 2c [O] . Santseharay Ramirez, Carlota Fernandez-Antunez, Lotte S. Mikkelsen, 2020

机译：细胞培养研究Sofosbuvir-Velpatasvir和Glecaprevir-Pibrentasvir对丙型肝炎病毒基因型2a2b和2c的抗性抗性的疗效和障碍
7. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study [O] . Peter Ruane, Simone I. Strasser, Edward J. Gane, 2019

机译：Sofosbuvir / Velpatasvir / Voxilaprevir为先前收到含Sofosbuvir / VelpataSvir的方案的HCV患者：恢复研究的结果

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

摘要

著录项

相似文献

相关主题

期刊订阅